Innovent Biologics Reports First-Half Growth and Advances Global Partnerships
2026-10-08 · 3 min read · AlphaGBM
At a glance
Economic Information Daily reported that Chen Bingliang, chief scientist of Innovent Biologics, Inc., said the company launched 20 marketed products over 15 years, spanning oncology, metabolic, autoimmune and ophthalmic diseases. In the first half of 2026, total revenue reached RMB8.618 billion, up 44.8% year on year, while product revenue rose 56.7% to RMB8.201 billion. Net profit under International Financial Reporting Standards increased 50.2% to RMB1.253 billion, exceeding the full-year 2025 level. The report attributed the expansion to the company’s established oncology portfolio and growing contributions from broader-pipeline products including mazdutide, SINTBILO and SINTBIMIN. It also said Innovent entered strategic collaborations worth more than RMB240 billion with Takeda, Eli Lilly, Pfizer and other companies over the past 10 months. The agreements covered more than 20 pipeline assets, including 5 co-development and co-commercialization projects. Innovent plans to achieve RMB20 billion in product revenue in 2027 and targets RMB35 billion to RMB40 billion in revenue by 2030, while seeking to advance at least 5 molecules into global multicenter Phase III studies and launch products in key European and US markets by 2030.
Summary
Economic Information Daily reported that Chen Bingliang, chief scientist of Innovent Biologics, Inc., said the company launched 20 marketed products over 15 years, spanning oncology, metabolic, autoimmune and ophthalmic diseases. In the first half of 2026, total revenue reached RMB8.618 billion, up 44.8% year on year, while product revenue rose 56.7% to RMB8.201 billion. Net profit under International Financial Reporting Standards increased 50.2% to RMB1.253 billion, exceeding the full-year 2025 level. The report attributed the expansion to the company’s established oncology portfolio and growing contributions from broader-pipeline products including mazdutide, SINTBILO and SINTBIMIN. It also said Innovent entered strategic collaborations worth more than RMB240 billion with Takeda, Eli Lilly, Pfizer and other companies over the past 10 months. The agreements covered more than 20 pipeline assets, including 5 co-development and co-commercialization projects. Innovent plans to achieve RMB20 billion in product revenue in 2027 and targets RMB35 billion to RMB40 billion in revenue by 2030, while seeking to advance at least 5 molecules into global multicenter Phase III studies and launch products in key European and US markets by 2030.